NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
At risk: Primary completion moved at least 3 years 2 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 27 versions: 27 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 1, 2027 to Nov 19, 2030 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 126 words
- Enrollment increased: 740 → 890 participants
- Trial sites expanded: 94 → 97 locations
- Study completion pushed from Oct 10, 2028 to Aug 19, 2031
- Secondary endpoints revised (16)
- Study description revised
- Minor Study sites: 94 to 96
- Minor Trial sites expanded: 91 → 94 locations
- Minor Study sites: 90 to 91
Notable Eligibility criteria expanded, about 51 words Show 4 more changesShow less
- Secondary endpoints: details revised at 2 of 16 entries
- Site details revised at 3 of 90 sites
- Collaborators: details revised at 1 of 1 entry
- Publications: details revised at 1 of 1 entry
- Minor Study sites: 89 to 90v22
- Minor Trial sites expanded: 86 → 89 locationsv21
- Minor Study sites: 85 to 86v20
- Minor Site details revised at 3 of 85 sitesv19
- Minor Study sites: 84 to 85v18
- Minor Study sites: 80 to 84v17
- Minor Study sites: 78 to 80v16
- Minor Study sites: 77 to 78v15
- Minor Study sites: 75 to 77v14
Notable Enrollment target: 400 to 740v13 Show 6 more changesShow less
- Primary completion date: Jun 30, 2025 to Sep 1, 2027
- Eligibility criteria expanded, about 305 words
- Study sites: 63 to 75
- Study completion date: Apr 30, 2026 to Oct 10, 2028
- Secondary endpoints: 15 to 16
- Study description expanded, about 3 words
- Minor Study sites: 62 to 63v12
- Minor Study sites: 61 to 62v11
- Minor Study sites: 60 to 61v10
- Minor Study sites: 57 to 60v9
- Minor Study sites: 56 to 57v8
- Minor Study sites: 54 to 56v7
- Minor Study sites: 52 to 54v6
- Minor Study sites: 10 to 52v5
- Notable Eligibility criteria shortened, about 2 words
- Study sites: 3 to 10
Notable Enrollment target: 120 to 400v3 Show 4 more changesShow less
- Eligibility criteria expanded, about 634 words
- Primary endpoints: 1 to 2
- Study sites: 1 to 3
- Secondary endpoints: 11 to 15
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 28, 2024 to Feb 26, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
Participants with locally advanced unresectable or metastatic cancer (melanoma, head and neck, gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, breast cancer, and cervical 2L/3L cancer) will receive an intravenous infusion of HER3-DXd monotherapy 5.6 milligrams per kilogram (mg/kg) every 3 weeks (Q3W).
Drugs: HER3-DXd
Sites
97 sites in 16 countries
United States 14, Japan 13, France 9, Spain 9, South Korea 8, Taiwan 8, United Kingdom 6, Australia 5, Belgium 5, Netherlands 5, Canada 4, Italy 4, Norway 3, China 2, Germany 1, Hungary 1